References of "Krzesinski, Jean-Marie"
     in
Bookmark and Share    
Full Text
See detailCardiac surgery and acute kidney injury.
LAGNY, Marc-Gilbert ULg; BLAFFART, Francine ULg; KOCH, Jean-Noël ULg et al

Conference given outside the academic context (2013)

Lecture about Cardiac surgery and acute kidney injury. Presentations of results about a retrospective study performed in the University Hospital of Liège and presentations about the protocol of a ... [more ▼]

Lecture about Cardiac surgery and acute kidney injury. Presentations of results about a retrospective study performed in the University Hospital of Liège and presentations about the protocol of a prospective study on the same topic. [less ▲]

Detailed reference viewed: 18 (3 ULg)
Full Text
Peer Reviewed
See detailCholecaciferol in haemodialysis patients: a randomized, double-blind, proof-of-concept and safety study
DELANAYE, Pierre ULg; WEEKERS, Laurent ULg; WARLING, Xavier et al

in Nephrology Dialysis Transplantation (2013), 28(7), 1779-1786

Background. The role of cholecalciferol supplementation in end-stage renal disease (ESRD) patients has been questioned. The objective of this randomized double-blinded study is to assess whether ... [more ▼]

Background. The role of cholecalciferol supplementation in end-stage renal disease (ESRD) patients has been questioned. The objective of this randomized double-blinded study is to assess whether cholecalciferol therapy can increase serum 25-hydroxyvitamin D [25(OH)D] levels in haemodialysed patients and the safety implications of this therapy on certain biological parameters and vascular calcifications score. Methods. Forty-three haemodialysis patients were randomized to receive placebo or cholecalciferol (25 000 IU) therapy every 2 weeks. The biological parameters, serum calcium, phosphorus, 25(OH)D and parathormone (PTH) levels, were monitored monthly for 12 consecutive months. Vascular calcifications were assessed by lateral X-ray radiography. Results. At baseline, the mean serum 25(OH)D levels were low and similar in both groups. Thirty patients (16 treated and 14 placebo) completed the study: 11 patients died (5 placebo and 6 treated), 1 patient dropped out and 1 patient was transplanted (both from the placebo group). After 1 year, the percentage of 25(OH)D deficient patients was significantly lower in the treated group. None of the patients developed hypercalcaemia. The PTH levels tended to increase over the study period under placebo and to decrease in the cholecalciferol group. The median changes in PTH levels from baseline to 1 year were statistically different between the two groups [+80 (−58 to 153) and −115 (−192 to 81) under placebo and cholecalciferol treatment, respectively, P = 0.02].The calcification scores increased equivalently in both groups (+2.3 per year). Conclusions. Cholecalciferol is effective and safe, and does not negatively affect calcium, phosphorus, PTH levels and vascular calcifications. Additional studies are needed to compare the impacts of nutritional and active vitamin D agents on vascular calcification and mortality. [less ▲]

Detailed reference viewed: 32 (10 ULg)
Full Text
Peer Reviewed
See detailEVOLVE: entre déception et optimisme
DELANAYE, Pierre ULg; Krzesinski, Jean-Marie ULg; CAVALIER, Etienne ULg

in Néphrologie & Thérapeutique (2013), 9(4), 241-245

Detailed reference viewed: 13 (6 ULg)
Full Text
Peer Reviewed
See detailMasked hypertension is associated with a high cardiovascular risk in hypertensive kidney transplant recipients
XHIGNESSE, Patricia ULg; Saint-Remy, Annie ULg; BONVOISIN, Catherine ULg et al

Poster (2013, June 16)

Objective: High blood pressure (BP) is a major risk factor for graft function in kidney transplant recipients (KTs) Our aim was to evaluate BP control in the office, but also in the ambulatory and home ... [more ▼]

Objective: High blood pressure (BP) is a major risk factor for graft function in kidney transplant recipients (KTs) Our aim was to evaluate BP control in the office, but also in the ambulatory and home settings, in stable KTs, ali treated for hypertension, and to characterize patients with masked hypertension (MHT). Design and Method: Three BP measurement techniques were used in 70 late KT patients, (mean age 56.5 years; 43 males): ambulatory BP monitoring (ABPM-Spacelab 90207) office (OBP) and home BP monitoring (HBPM)- (OMRON M6). Carotid­ femoral pulse wave velocity was measured (Sphygmocor) as weil as a calcification score (arteries) and the systolic ankle brachial index (ABI) as recommended. The period since transplantation was 6.9±6.6 years, the mean GFR was 65.6±24±ml/min, Body Mass Index was 25.8±4.7 kg/m2 and the number of antihypertensive drug was 2.1±1 pills/d. Results: Uncontrolled hypertension (HTN) remained frequent in our treated population, 46 % were still hypertensive in the office, 39% using ABPM and 43% with HBPM. The proportion of MHT was 22% whatever the out-of-clinic method used, with more males, more overweight (BMI between, 25-30). lnterestingly when compared with controlled KTs (i.e both OBP and Daytime ABP controlled or both OBP and HBP controlled), using either ABPM or Home BP, patients with MHT had significantly higher PWV, a higher aortic augmentation pressure (AP), a higher calcification score and a higher ABI. However we did not find any significant impact of graft survival, immunosuppressive drugs, smoking habits, diabetes, or alcohol use. Conclusion: A high percentage of uncontrolled HTN was noted by OBP, but also by ABPM and HBPM despite antihypertensive treatment. MHT was frequently observed in KTs. This particular HT subtype, either defined by OBP vs ABPM or by OBP vs HBP, was significantly associated with major markers of arterial stiffness. So, MHT is associated with a high cardiovascular (cv) risk and therefore has to be manage to reduce incidence of cv events and graft loss. [less ▲]

Detailed reference viewed: 22 (4 ULg)
Full Text
See detailPrise en charge de l'hyperuricémie
Krzesinski, Jean-Marie ULg

Conference (2013, May 30)

Plan du diaporama : •Métabolisme de l’acide urique •Risques de l’hyperuricémie•Goutte •Autres •Traitements •De la crise aiguë •De fond •Hyperuricémie asymptomatique •Cas cliniques

Detailed reference viewed: 35 (2 ULg)
Full Text
Peer Reviewed
See detailStratification du risque cardiovasculaire selon la fonction rénale
Krzesinski, Jean-Marie ULg

in Journal de Cardiologie [= JDC] = Tijdschrift voor Cardiologie [= TVC] (2013), 3

Le risque cardiovasculaire est particulièrement important chez le patient qui a une insuffisance rénale (GFR abaissée et/ou albuminurie présente). Il est souvent sous-estimé en utilisant la table SCORE ... [more ▼]

Le risque cardiovasculaire est particulièrement important chez le patient qui a une insuffisance rénale (GFR abaissée et/ou albuminurie présente). Il est souvent sous-estimé en utilisant la table SCORE par l'agrégation de facteurs de risque traditionnels et non traditionnels quand i y a une IR, à identifier correctement et précocement. La prise en charge de ces facteurs agit sur la prévention à la fois rénale et cardiovasculaire. [less ▲]

Detailed reference viewed: 22 (4 ULg)
Full Text
Peer Reviewed
See detailMDRD VERSUS CKD-EPI EQUATIONS TO ESTIMATE GLOMERULAR FILTRATION RATE IN OBESE PATIENTS
BOUQUEGNEAU, Antoine ULg; CAVALIER, Etienne ULg; Krzesinski, Jean-Marie ULg et al

in Nephrology Dialysis Transplantation (2013, April 18), 28(supplément 1), 117-139

Introduction and Aims: Obesity is recognized as a risk factor both for the development and progression of chronic kidney disease (CKD). Estimating glomerular filtration rate (GFR) is thus especially ... [more ▼]

Introduction and Aims: Obesity is recognized as a risk factor both for the development and progression of chronic kidney disease (CKD). Estimating glomerular filtration rate (GFR) is thus especially important to follow these patients. We have tested the performances of two creatinine-based equations, namely the MDRD and CKD-EPI equations, in an obese population. Conclusions :Both in the global and subgroup analyses, the CKD-EPI equation did not outperform the MDRD study equation. The performances of both equations were worse in CKD patients. These two conclusions were still valid if indexed GFR was considered. [less ▲]

Detailed reference viewed: 20 (1 ULg)
Full Text
See detailKDIGO – prise en charge de l’hypertension artérielle en dialyse
Krzesinski, Jean-Marie ULg

Conference (2013, March 28)

1. A lower target may be chosen in CKD patients with proteinuria but after individualized risk-benefit assessment. The price to pay is a need for a higher number of antiHTA drugs and a risk of more ... [more ▼]

1. A lower target may be chosen in CKD patients with proteinuria but after individualized risk-benefit assessment. The price to pay is a need for a higher number of antiHTA drugs and a risk of more frequent side-effects. 2. Confirmation of a high BP level is necessary through out-of-the clinic BP measurement In CKD, ABPM offers night-time BP information useful for CV and renal risk evaluation. BP variability is a new point to be considered in the future. Proteinuria but also other specific risk factors (Phosphate, anemia, inflammation,..) should be integrated in the management of hypertension in CKD [less ▲]

Detailed reference viewed: 27 (2 ULg)
Full Text
See detailIntérêts et limites de la dialyse nocturne
Krzesinski, Jean-Marie ULg

Conference (2013, March 14)

Detailed reference viewed: 11 (1 ULg)
Full Text
Peer Reviewed
See detailCreatinine - or cystatin C - based equations to estimate glomerular filtration in the general population: impact on the epidemiology of chronic kidney disease
DELANAYE, Pierre ULg; CAVALIER, Etienne ULg; Moranne, Olivier et al

in BMC Nephrology (2013), 14

Chronic kidney disease (CKD) is a major issue in public health. Its prevalence has been calculated using estimation of glomerular filtration rate (GFR) by the creatinine-based equations developed in the ... [more ▼]

Chronic kidney disease (CKD) is a major issue in public health. Its prevalence has been calculated using estimation of glomerular filtration rate (GFR) by the creatinine-based equations developed in the Modified Diet in Renal Disease (MDRD) and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) study. Recently, new equations based either on cystatin C (CKD-EPI Cys) or both cystatin and creatinine (CKD-EPI mix) have been proposed by the CKD-EPI consortium. The aim of this study was to measure the difference in the prevalence of stage 3 CKD, defined as an estimated GFR less than 60 mL/min/1.73 m2, in a population using these four equations. METHODS: CKD screening was performed in the Province of Liege, Belgium. On a voluntary basis, people aged over 50 years have been screened. GFR was estimated by the four equations. Stage 3 CKD was defined as a GFR less than 60 mL/min/1.73 m2. RESULTS: The population screened consisted of 4189 people (47% were men, mean age 63 +/- 7y). Their mean serum creatinine and plasma cystatin C levels were 0.88 +/- 0.21 mg/dL and 0.85 +/- 0.17 mg/L, respectively. The prevalence of CKD in this population using the MDRD, the CKD-EPI, the CKD-EPI Cys and the CKD-EPI mix equations was 13%, 9.8%, 4.7% and 5%, respectively. The prevalence of CKD was significantly higher with the creatinine-based (MDRD and the CKD-EPI) equations compared to the new cystatin C-based equations. CONCLUSIONS: Prevalence of CKD varies strongly depending on the method used to estimate GFR. Such discrepancies are of importance and must be confirmed and explained by additional studies, notably by studies using GFR measured with a reference method [less ▲]

Detailed reference viewed: 49 (19 ULg)
Full Text
See detailStratification du risque cardiovasculaire selon la fonction
Krzesinski, Jean-Marie ULg

Conference (2013, March 09)

Detailed reference viewed: 17 (2 ULg)
Full Text
See detailHypertension artérielle résistante : place actuelle de la dénervation rénale dans sa prise en charge
Krzesinski, Jean-Marie ULg

Conference (2013, March 05)

HTA résistante touche 8% de la population hypertendue Nécessité d’une approche méthodique pour débusquer l’erreur dans la prise en charge Importance des médicaments interférant, du gain de poids et de ... [more ▼]

HTA résistante touche 8% de la population hypertendue Nécessité d’une approche méthodique pour débusquer l’erreur dans la prise en charge Importance des médicaments interférant, du gain de poids et de l’alimentation trop salée. Recherche d’un SAHOS Haute dose de diurétique et souvent association avec la spironolactone. Et si cela résiste? …dDénervation rénale? 1% des hypertendus traités! [less ▲]

Detailed reference viewed: 19 (0 ULg)
Full Text
Peer Reviewed
See detailParathormone and bone-specific alkaline phosphatase for the follow-up of bone turnover in hemodialysis patients : Is it so simple?
DELANAYE, Pierre ULg; DUBOIS, Bernard ULg; JOURET, François ULg et al

in Clinica Chimica Acta (2013), 417

Background: Chronic Kidney Disease (CKD) is associated with mineral and bone disorders (MBD). International guidelines suggest that levels of serum parathormone (PTH) or bone-specific alkaline phosphatase ... [more ▼]

Background: Chronic Kidney Disease (CKD) is associated with mineral and bone disorders (MBD). International guidelines suggest that levels of serum parathormone (PTH) or bone-specific alkaline phosphatase (b-ALP) can be used to evaluate MBD in dialysis patients. The evidence remains moderate and based on transversal studies. <br />Methods: We retrospectively investigated the variations of PTH (ΔPTH) and b-ALP (Δb-ALP) serum concentrations over a short (6-weeks) and a long (one-year) period in a monocentric hemodialysis population. The proportion of patients reaching the critical difference (CD) (50% for PTH and 25% for b-ALP) was calculated. <br />Results: Seventy-seven patientswere included. A significant correlation between PTHand b-ALP levelswas found at baseline (r=0.51). By contrast, no correlation was observed between ΔPTH and Δb-ALP over a 6-week interval (r=0.07). The CD for PTH and b-ALP was reached by 19 and 11 patients, respectively, with 2 patients showing consistent variations of both biomarkers. One year later, measurements were repeated in 48 survivors. <br />No correlation was found between ΔPTH and Δb-ALP (r=0.27). The CD for PTH or b-ALP was reached by 24 patients and 28 patients, respectively, with 6 patients (12.5%) showing opposite results for both biomarkers. <br />Conclusion: This study shows the lack of correlation between ΔPTH and Δb-ALP over time in patients under chronic hemodialysis. [less ▲]

Detailed reference viewed: 40 (17 ULg)